Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease
Author(s): Federica Piani , Lorenzo Annesi , Claudio Borghi Added: 11 months ago

Prevention & Chronic Conditions

Heart Failure
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Samuel Sherratt
Job title: Scientific Director
Dr Samuel Sherratt is the scientific director at Elucida Research in Beverly, MA (US). He is also a Visiting Professor at the Mount Sinai Fuster Heart Hospital at the Icahn School of Medicine in New York City, NY.His research interests include elucidating novel mechanisms of action of omega-3 fatty acids, lipoprotein metabolism, endothelial cell function and disease pathophysiology, and X-ray… View more
Job title: Director
AHA 24: The ALPACAR Trial
Author(s): Steven E Nissen Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD).Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).ALPACAR is a phase 2, randomized, five-arm, placebo-controlled trial… View more

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Maria Fernández García , Beatriz Nieves Ureña , Alberto Alen Andrés , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
Andrew Mente
Job title: Associate Professor – Department of Health Research Methods, Evidence, and Impact (HEI)
Dr Andrew Mente is a Principal Investigator for the Epidemiology program at the Population Health Research Institute and Associate Professor – Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University. Dr Mente received his doctoral degree in Epidemiology from the University of Toronto and completed post-doctoral training in cardiovascular epidemiology at McMaster… View more
30th Annual Meeting of the ISCP
Author(s): Maria Victoria Luis Valle , Adela Castro Garcia , Diego De la Eranueva Calvo , et al Added: 1 month ago

Prevention & Chronic Conditions

Guidelines & Statements
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 7 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions